Results 151 to 160 of about 6,119 (209)

Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study. [PDF]

open access: yesTher Adv Psychopharmacol
Cuomo A   +9 more
europepmc   +1 more source

Esketamine for treatment resistant depression

Expert Review of Neurotherapeutics, 2019
Introduction: Treatment Resistant Depression (TRD) is a common and burdensome condition with poor outcomes and few treatment options. Esketamine is the S-enantiomer of ketamine and has recently been FDA approved in the United States for treating depression that has failed to respond to trials of two or more antidepressants.
Jennifer Swainson   +2 more
exaly   +5 more sources

The antidepressant effect and safety of non-intranasal esketamine: A systematic review [PDF]

open access: yesJournal of Psychopharmacology, 2022
BACKGROUND: The introduction of esketamine into the field of psychiatry comes on the heels of excitement from studies on racemic ketamine. While the intranasal route has been the most studied to date, other modes of administration of esketamine may also ...
Sanne Y Smith-Apeldoorn   +2 more
exaly   +2 more sources

Home - About - Disclaimer - Privacy